BACKGROUND: Vitamin D-binding protein (DBP) and catabolism have not been examined in the clinical setting of childhood chronic kidney disease (CKD). METHODS: The concentrations of serum vitamin D {25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], 24,25-dihydroxyvitamin D [24,25(OH)(2)D]}, DBP, intact parathyroid hormone (iPTH), and fibroblast growth factor-23 (FGF23) were measured in 148 participants with CKD stages 2-5D secondary to congenital anomalies of the kidney/urinary tract (CAKUT), glomerulonephritis (GN), or focal segmental glomerulosclerosis (FSGS). Free and bioavailable 25(OH)D concentrations were calculated using total 25(OH)D, albumin, and DBP concentrations. RESULTS: The concentrations of all vitamin D metabolites were lower with more advanced CKD (p < 0.001) and glomerular diagnoses (p ≤ 0.002). Among non-dialysis participants, DBP was lower in FSGS versus other diagnoses (FSGS-dialysis interaction p = 0.02). Winter season, older age, FSGS and GN, and higher FGF23 concentrations were independently associated with lower concentrations of free and bioavailable 25(OH)D. Black race was associated with lower total 25(OH)D and DBP, but not free or bioavailable 25(OH)D. 24,25(OH)(2)D was the vitamin D metabolite most strongly associated with iPTH. Lower 25(OH)D and higher iPTH concentrations, black race, and greater CKD severity were independently associated with lower levels of 24,25(OH)(2)D, while higher FGF23 concentrations and GN were associated with higher levels of 24,25(OH)(2)D. CONCLUSIONS: Children with CKD exhibit altered catabolism and concentrations of DBP and free and bioavailable 25(OH)D, and there is an important impact of their underlying disease.
BACKGROUND:Vitamin D-binding protein (DBP) and catabolism have not been examined in the clinical setting of childhood chronic kidney disease (CKD). METHODS: The concentrations of serum vitamin D {25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], 24,25-dihydroxyvitamin D [24,25(OH)(2)D]}, DBP, intact parathyroid hormone (iPTH), and fibroblast growth factor-23 (FGF23) were measured in 148 participants with CKD stages 2-5D secondary to congenital anomalies of the kidney/urinary tract (CAKUT), glomerulonephritis (GN), or focal segmental glomerulosclerosis (FSGS). Free and bioavailable 25(OH)D concentrations were calculated using total 25(OH)D, albumin, and DBP concentrations. RESULTS: The concentrations of all vitamin D metabolites were lower with more advanced CKD (p < 0.001) and glomerular diagnoses (p ≤ 0.002). Among non-dialysis participants, DBP was lower in FSGS versus other diagnoses (FSGS-dialysis interaction p = 0.02). Winter season, older age, FSGS and GN, and higher FGF23 concentrations were independently associated with lower concentrations of free and bioavailable 25(OH)D. Black race was associated with lower total 25(OH)D and DBP, but not free or bioavailable 25(OH)D. 24,25(OH)(2)D was the vitamin D metabolite most strongly associated with iPTH. Lower 25(OH)D and higher iPTH concentrations, black race, and greater CKD severity were independently associated with lower levels of 24,25(OH)(2)D, while higher FGF23 concentrations and GN were associated with higher levels of 24,25(OH)(2)D. CONCLUSIONS:Children with CKD exhibit altered catabolism and concentrations of DBP and free and bioavailable 25(OH)D, and there is an important impact of their underlying disease.
Authors: F F Safadi; P Thornton; H Magiera; B W Hollis; M Gentile; J G Haddad; S A Liebhaber; N E Cooke Journal: J Clin Invest Date: 1999-01 Impact factor: 14.808
Authors: E Ishimura; Y Nishizawa; M Inaba; N Matsumoto; M Emoto; T Kawagishi; S Shoji; S Okuno; M Kim; T Miki; H Morii Journal: Kidney Int Date: 1999-03 Impact factor: 10.612
Authors: T O Jemielita; M B Leonard; J Baker; S Sayed; B S Zemel; J Shults; R Herskovitz; M R Denburg Journal: Osteoporos Int Date: 2015-09-10 Impact factor: 4.507
Authors: Virginia A Stallings; Joan I Schall; Mary L Hediger; Babette S Zemel; Florin Tuluc; Kelly A Dougherty; Julia L Samuel; Richard M Rutstein Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: Christine B Sethna; Derek K Ng; Shuai Jiang; Jeff Saland; Bradley A Warady; Susan Furth; Kevin E Meyers Journal: Pediatr Nephrol Date: 2019-03-22 Impact factor: 3.714
Authors: Rene F Chun; Bradford E Peercy; Eric S Orwoll; Carrie M Nielson; John S Adams; Martin Hewison Journal: J Steroid Biochem Mol Biol Date: 2013-10-04 Impact factor: 4.292
Authors: Evelyn Hsieh; Liana Fraenkel; Yang Han; Weibo Xia; Karl L Insogna; Michael T Yin; Ting Zhu; Xinqi Cheng; Taisheng Li Journal: AIDS Date: 2016-07-31 Impact factor: 4.177
Authors: Juhi Kumar; Kelly McDermott; Alison G Abraham; Lisa Aronson Friedman; Valerie L Johnson; Frederick J Kaskel; Susan L Furth; Bradley A Warady; Anthony A Portale; Michal L Melamed Journal: Pediatr Nephrol Date: 2015-08-26 Impact factor: 3.714
Authors: Michelle R Denburg; Andrew N Hoofnagle; Samir Sayed; Jayanta Gupta; Ian H de Boer; Lawrence J Appel; Ramon Durazo-Arvizu; Krista Whitehead; Harold I Feldman; Mary B Leonard Journal: J Bone Miner Res Date: 2016-06 Impact factor: 6.741